SNB-19 In Vivo Anti-Tumor Efficacy Assay

This assay is to provide SNB-19-based In Vivo Anti-Tumor Efficacy Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

SNB-19

Human

SNB-19 is a human glioblastoma cell line that was isolated from a left parieto-occipital glioblastoma of a 47-year-old male patient in 1980. In a 1988 study, published in Cancer Research Journal, the SNB-19 cell line was the most clonogenic in soft agar and showed the most tumorigenicity in nude mice.

Glioblastoma

Oncology

In Vivo Anti-Tumor Efficacy Assay

SNB-19-cell based In Vivo Anti-Tumor Efficacy Assay

After positive anti-tumor efficacy data is concluded using in vitro assays, we can start to initiate in vivo anti-tumor efficacy studies. Creative Biolabs offers a wide variety of PDX or CDX models to facilitate the efficacy studies. This assy will be used to evaluate the anti-tumor efficacy of your therapeutic candidates, such as small molecules, antibodies, CARTs or other biologics. Detailed group set up and other plans will be discussed according to your specific requirements.

Oncology In Vivo Assays